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Pulmonary arterial hypertension (PAH) is characterized by increased vasoconstriction, extensive remodeling of 
small intrapulmonary arteries, and right heart hypertrophy. 
Endothelial cell injury followed by vascular endothelial and 
smooth muscle proliferation and endothelial-to-mesenchymal 
transition contribute to the vascular pathology of PAH.1
Editorial, see p 6 
Meet the First Author, see p 3
Inflammation, driven in part by the activation of NF-κB 
(nuclear factor kappa B), and reduced endothelial BMPRII 
(bone morphogenetic protein receptor II) expression and/
or function are recognized as key factors in endothelial in-
jury and dysfunction that instigate and propagate adverse re-
modeling of the pulmonary arteries.2,3 Expression of BMPRII 
protein is constitutively regulated by lysosomal degradation in 
vascular cells,4 but regulatory mechanisms have not been fully 
characterized.
We have recently shown increased expression of CLIC4 
(chloride intracellular channel 4) in the lungs of PAH patients 
and PAH animals.5 CLIC4 is a member of CLIC family of 
proteins (CLIC1-6) involved in the regulation of cell prolif-
eration, apoptosis, angiogenesis, and differentiation.6,7 In ex-
perimental models of PAH, CLIC4 expression increases in the 
lung but not in systemic tissues, and deletion of CLIC4 gene 
in mice prevents development of hypoxia-induced pulmonary 
hypertension (PH).5 CLIC4, like BMPRII localizes preferen-
tially to the pulmonary vascular endothelium and induces the 
NF-kB-dependent activation of HIF (hypoxia-inducible fac-
tor),5 but its contribution to BMPRII signaling is not fully un-
derstood. While BMPRII knockdown does not alter CLIC4 
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Rationale: Increased expression of CLIC4 (chloride intracellular channel 4) is a feature of endothelial dysfunction 
in pulmonary arterial hypertension, but its role in disease pathology is not fully understood.
Objective: To identify CLIC4 effectors and evaluate strategies targeting CLIC4 signaling in pulmonary hypertension.
Methods and Results: Proteomic analysis of CLIC4-interacting proteins in human pulmonary artery endothelial 
cells identified regulators of endosomal trafficking, including Arf6 (ADP ribosylation factor 6) GTPase activating 
proteins and clathrin, while CLIC4 overexpression affected protein regulators of vesicular trafficking, lysosomal 
function, and inflammation. CLIC4 reduced BMPRII (bone morphogenetic protein receptor II) expression and 
signaling as a result of Arf6-mediated reduction in gyrating clathrin and increased lysosomal targeting of the 
receptor. BMPRII expression was restored by Arf6 siRNA, Arf inhibitor Sec7 inhibitor H3 (SecinH3), and inhibitors 
of clathrin-mediated endocytosis but was unaffected by chloride channel inhibitor, indanyloxyacetic acid 94 or Arf1 
siRNA. The effects of CLIC4 on NF-κB (nuclear factor-kappa B), HIF (hypoxia-inducible factor), and angiogenic 
response were prevented by Arf6 siRNA and SecinH3. Sugen/hypoxia mice and monocrotaline rats showed elevated 
expression of CLIC4, activation of Arf6 and NF-κB, and reduced expression of BMPRII in the lung. These changes 
were established early during disease development. Lung endothelium–targeted delivery of CLIC4 siRNA or 
treatment with SecinH3 attenuated the disease, reduced CLIC4/Arf activation, and restored BMPRII expression in 
the lung. Endothelial colony–forming cells from idiopathic pulmonary hypertensive patients showed upregulation 
of CLIC4 expression and Arf6 activity, suggesting potential importance of this pathway in the human condition.
Conclusions: Arf6 is a novel effector of CLIC4 and a new therapeutic target in pulmonary hypertension.  (Circ Res. 
2019;124:52-65. DOI: 10.1161/CIRCRESAHA.118.313705.)
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expression,5 CLIC4 affects migratory responses of pulmonary 
artery smooth muscle cells downstream of BMPRII/BMP 
(bone morphogenetic protein) signaling.8
Targeting CLIC4 with specific small molecule inhibitors 
has been challenging because of high homology among CLIC 
proteins. The only existing inhibitor, chloride channel blocker 
indanyloxyacetic acid 94 used in CLIC research, has a broad 
spectrum of intracellular targets.7 Interestingly, despite their 
name as intracellular chloride channels, CLIC proteins form 
poorly selective anion channels and their main function does 
not depend on chloride conductance.9 CLIC4 localizes to en-
docytotic vesicles10,11 and may play a role in the regulation 
of vesicular trafficking. Vesicular trafficking is controlled 
by Arf (ADP ribosylation factor) proteins, Ras-related small 
GTPases that cycle between an active, GTP-bound and an 
inactive, GDP-bound conformation.12 Arf proteins are acti-
vated by GEFs (guanine exchange factors) that stimulate ex-
change of GDP for GTP, thereby switching “on” the GTPase 
and GAPs (GTPase-activating proteins), which facilitate GTP 
hydrolysis, thereby switching “off” the GTPase.
Here, we applied an unbiased proteomic screen to iden-
tify new targets in CLIC4 signaling pathway and to elucidate 
CLIC4 contribution to the vascular pathology in PAH. We are 
first to show a new regulatory pathway in BMPRII signaling 
involving CLIC4-induced activation of the endosomal traffick-
ing regulator Arf6. We also show that CLIC4 siRNA or Arf 
inhibitor Sec7 inhibitor H3 (SecinH3) prevent development of 
PH in 2 preclinical rodent models of PAH.
Methods
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE repository with the 
dataset identifier PXD008709 for CLIC4-interacting proteins and 
PXD008714 for proteomics of CLIC4 overexpressing human pulmo-
nary artery endothelial cells. Additional data can be obtained from the 
corresponding author on request. Detailed methods section is availa-
ble in the Online Data Supplement.
Endothelial Cell Culture and Treatments
Human pulmonary artery endothelial cells (HPAECs; PromoCell) 
were cultured in the endothelial growth medium 2 (PromoCell). 
Overexpression of hemagglutinin-tagged CLIC4 (kind gift from 
Professor Stuart H. Yuspa, Laboratory of Cancer Biology and 
Genetics, Centre for Cancer Research, Bethesda) under tetracycline 
control or AdCLIC4shRNA (Welgen, Inc) was induced by adenovi-
ral gene transfer.5 AdGFP (Vector Biolabs) or AdTet-off were used 
as adenoviral controls (Adcontrol). In some experiments, the cells 
were exposed to hypoxia (2% O2, 5% CO2, 92% N2) or were incu-
bated with human recombinant TNF-α (tumor necrosis factor α; 10 
μg/L; 210-TA-020k, R&D), SecinH3 (10 mg/L; 2849, R&D), NF-
κB inhibitor, BAY 117085 (10 µmol/L; Sigma-Aldrich), or a chlo-
ride channel inhibitor, indanyloxyacetic acid 94 (100 µmol/L, I117, 
Sigma-Aldrich) for 24 hours before cell lysis or immunostaining, 
while human BMP9 (bone morphogenetic protein 9; 10 μg/L; 3209-
BP, R&D) or TGF-β (transforming growth factor; 10 μg/L; 240-B-
010, R&D) were added to the cells for 1 hour at 37°C.
Nonstandard Abbreviations and Acronyms
Arf ADP ribosylation factor
BMP bone morphogenetic protein
BMPRII bone morphogenetic protein receptor II
CLIC4 chloride intracellular channel 4
ECFCs endothelial colony–forming cells
GAPs GTPase-activating proteins
GEFs guanine exchange factors
HPAECs human pulmonary artery endothelial cells
LAMP1 lysosomal-associated membrane protein 1
MHC-I major histocompatibility complex molecule-I
NF-κB nuclear factor kappa B
PAH pulmonary arterial hypertension
PH pulmonary hypertension
RVH right ventricular hypertrophy
RVSP right ventricular systolic pressure
TfR transferrin receptor
TGF-β transforming growth factor beta
TNF-α tumor necrosis factor α
Novelty and Significance
What Is Known?
• Reduced expression of BMPRII (bone morphogenetic protein receptor 
II) is a feature of occlusive vasculopathy in pulmonary arterial 
hypertension (PAH).
• BMPRII degradation is increased in PAH.
• CLIC4 (chloride intracellular channel 4) contributes to vascular remod-
eling in PAH, but its effect on BMPRII function is not known.
What New Information Does This Article Contribute?
• CLIC4 activates vesicular trafficking regulator, Arf6 (ADP ribosylation 
factor 6).
• Activation of Arf6 inhibits membrane recycling of BMPRII and prompts 
proteolytic degradation of the receptor.
• Arf6 is activated in the lungs of PAH animals and endothelial cells from 
PAH patients.
• Silencing of endothelial CLIC4 or inhibition of Arf6 activity with Sec7 
inhibitor H3 (SecinH3) prevent development of pulmonary hypertension 
in preclinical models of the disease.
In response to stress conditions, such as inflammation or oxi-
dative damage, endothelial cells in the pulmonary hypertensive 
lung express high levels of CLIC4. CLIC4 binds proteins that 
control recycling of membrane receptors, such as clathrin and 
Arf6 activating proteins, GIT1 and GIT2. As a result, the BMPRII 
receptor, which in normal cells is continuously internalized 
and then recycled back to the cell surface, is promptly trans-
ported to lysosomes and degraded. Inhibition of Arf6 activity 
with cytohesin inhibitors, such as SecinH3, restores BMPRII 
expression and reduces inflammatory responses in cultured 
endothelial cells and the lungs of animal models of pulmonary 
hypertension and prevents development of the disease in pre-
clinical models of PAH. In summary, we identify a novel path-
way involving activation of the endocytotic trafficking regulator, 
Arf6. Inhibition of the CLIC4/Arf6 pathway represents a novel 
treatment strategy for PAH.
54  Circulation Research  January 4, 2019
Blood-Derived Human Endothelial Cell Culture
Human endothelial colony–forming cells (ECFCs) were derived from 
peripheral blood samples as previously described.5 Venous blood 
samples were obtained with local ethics committee approval. and 
informed written consent from healthy volunteers and patients with 
idiopathic PAH was obtained (clinical information is shown in the 
Online Table I).
Proteomic Analysis
HPAECs were left untreated or were infected with Adcontrol or 
AdCLIC4. Twenty-four hours post-infection, the cells were lysed and 
subjected to SDS-PAGE (n=4/group). Hemagglutinin-tagged CLIC4 
were purified using a hemagglutinin-tagged protein purification kit 
(3320, MBL Company Ltd) followed by SDS-PAGE separation. 
Following in-gel digestions, the resultant tryptic peptides from each 
experiment were separated on a nano-liquid chromatography–tandem 
mass spectrometry for identification and quantitation. For overexpres-
sion analysis, differentially expressed proteins were identified on the 
basis of at least 1.5-fold difference in abundance in AdCLIC4 versus 
AdControl with P value <0.05. Ingenuity Pathway Analysis (Qiagen) 
was used for mapping the identified proteins to known biological path-
ways. For CLIC4-interacting protein analysis, only the proteins that 
were unique to the hemagglutinin-tag purification fraction were listed.
Cell Transfection
Electroporation of plasmid DNA with BMPRII-GFP (RG208673; 
Origene), pRK5F-PPM1A (protein phosphatase 1A plasmid DNA; kind 
gift of Professor Xin-Hua Feng, Baylor College of Medicine, TX), pmaxG-
FP (Lonza), YFP-GGA1 (yellow fluorescent protein–labelled golgi-associ-
ated, gamma adaptin ear-containing, ARF-binding protein 1)13 or mCherry 
clathrin14 (kind gift of Professor James Keen, Thomas Jefferson University, 
Philadelphia), Silencer Select human siRNAs: negative control siRNA 
No. 1 (4390843; Ambion), Arf1 siRNA (4390824, ID: s1552; Ambion), 
Arf6 siRNA (4390824, ID: s1565; Ambion) were conducted using the 
Amaxa Basic Nucleofector Kit (VPI-1001, Lonza). Cell responses were 
studied 48 hours post-transfection. In some experiments, silencing RNAs 
were transfected into cells using Lipofectamine RNAiMAX (13778075; 
ThermoFisher Scientific) according to the manufacturer’s protocol.
Immunostaining and Western Blot Analysis
CLIC4, p65 NF-κB, BMPRII, Smad1, Smad5 and p-Smad1,5, Smad3 
and p-Smad3, Arf1, Arf6, LAMP-1 (lysosomal-associated membrane 
protein 1), β-actin, and filamentous-actin were studied by Western 
blotting and immunofluorescence in cells, cell lysates, or tissue sec-
tions, as appropriate.
Microscale Thermophoresis
Microscale thermophoresis was performed to study the interaction be-
tween  enhanced green fluorescent protein–labelled G-protein–coupled 
receptor kinase-interacting protein 1 (GIT1; 15223; Adgene) in hu-
man embryonic kidney 293 cells lysate and a serial dilution of puri-
fied CLIC4 (ab104744; Abcam) using Monolith NT.115 instrument 
according to the manufacturer’s protocol (NanoTemper Technologies, 
Germany). The assay was performed with constant concentration of 
ECFP-labeled GIT1 at 20 nmol/L and varying concentrations of CLIC4.
Arf6 Activity Assay
Arf6 and Arf1 activity (GTP-binding) assays were performed accord-
ing to the manufacturer’s protocol (BK033-S and BK032-S, respec-
tively; Cytoskeleton, Inc).
Proximity Ligation Assay
Intracellular distribution and spatial proximity of CLIC4 and BMPRII 
in HPAECS were studied with Duolink in situ proximity ligation as-
say according to manufacturer’s instructions (Olink Biosciences; 
Sigma-Aldrich). Samples were mounted with Duolink mounting 
media, and cell images were taken under a fluorescent confocal mi-
croscope. The number of fluorescent puncta indicative of the close 
proximity of the 2 molecules was scored by measuring the intensity 
of fluorescence in each cell with Image J.
NF-κB Luciferase Reporter Assay and Nuclear 
Translocation of p65NF-κB
NF-κB luciferase reporter assay was performed as previously de-
scribed.5 Nuclear translocation of p65 NF-κB was studied with Image 
J. The white pixel area, marking nuclear NF-κB, was used to quanti-
tate p65 NF-κB translocation in cells and tissues.
HIF Activation and Tube Formation Assay
HIF-1α stabilization and tube formation in matrigel were studied as 
previously described.5
Quantification of Gyrating (G-) Clathrin
HPAECs transfected with plasmid encoding YFP-GGA1 were in-
fected with Adcontrol or AdCLIC4 and incubated with, or without, 
SecinH3 (10 mg/L), as appropriate. Twenty-four hours later, live 
cells were recorded under the confocal laser scanning fluorescence 
microscope (Zeiss LSM-780 at the facility for imaging by light mi-
croscopy) to collect frame image stacks. Quantification of gyrating 
clathrin (G-clathrin) was performed as previously described.15
Lysosome Markers and Lysosome Acidification
Lysosome content was evaluated by measuring fluorescence inten-
sity of confluent cells immunostained for lysosome marker protein 
LAMP1, while lysosome acidification was evaluated with pHrodo Red, 
succinimidyl ester (pHrodo Red, SE, P36600; Thermofisher Scientific), 
according to the manufacturer’s protocol. pHrodo Red dye conjugates 
are nonfluorescent outside the cell, but fluoresce brightly red in phago-
somes. Three confocal images comprising ≈200 cells/coverslip on 3 
coverslips per treatment in 3 separate experiments, were analyzed.
Clathrin-Mediated Endocytosis
Clathrin-mediated endocytosis was evaluated by measuring the up-
take of transferrin from Human Serum, Alexa Fluor 488 Conjugate 
(T13342, Thermofisher Scientific). Clathrin-independent endocytosis 
was measured by intake of mouse monoclonal antibodies directed 
toward MHC-I (major histocompatibility complex I; clone w6/32, 
Biolegend) or control mouse monoclonal anti-cytokeratin 14 antibody 
(ab7800; Abcam; antibodies directed against intracellular target), fol-
lowed by removal of the unbound antibody by low pH acid wash, 
fixation, and staining with secondary fluorescein isothiocyanate–la-
beled goat anti-mouse antibody (115-095; Jackson Laboratories).16 
In some experiments, control (Adcontrol) and CLIC4-overexpressing 
(AdCLIC4) cells were treated with 20 mg/L protein synthesis inhib-
itor cycloheximide (CAS 66-81-9; Santa Cruz Biotechnology), with 
or without the endocytosis inhibitor Pitsop2 (20 μmol/L; ab120687; 
Abcam)16 or Pitstop2-negative control (20 μmol/L; ab120688; 
Abcam,) for 2 hours. Pitsop2-negative control is chemically related to 
Pitstop2 but does not block receptor-mediated endocytosis. BMPRII 
expression was analyzed by Western blotting.
Plasma Membrane Anion Permeability
Cell plasma membrane anion permeability was assessed using the 
Chloride Channel Assay Kit from Abcam (ab176767), which meas-
ures passive cellular iodide uptake, according to the manufacturer’s 
protocol.
Animal Experiments
All experiments were conducted in accordance to the UK Home 
Office Animals (Scientific Procedures) Act 1986 (London, United 
Kingdom). Detailed description of experimental procedures can be 
found the Online Data Supplement. All animals were randomly allo-
cated to groups, and all personnel involved in data collection and anal-
ysis (hemodynamics and histopathologic measurements) were blinded 
to the treatment status of each animal. Only weight- and age-matched 
males were included for experimentation as, in contrast to the human 
clinical studies, most animal studies have shown that female sex and 
estrogen supplementation have a protective effect against PAH.17
Three series of experiments were conducted. In the first 2 se-
ries of experiments, a liposomal formulation DACC/CLIC4siRNA 
or SecinH3 were delivered to Sugen/hypoxia mice from the start of 
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disease development. In the third series of experiments, SecinH3 was 
delivered to monocrotaline rats 8 days post monocrotaline injection.
In Sugen/hypoxia mouse model of PAH, adult male C57/Bl6 mice 
(20 g, 8/group) were injected subcutaneously with Sugen (SU5416; 
20 mg/kg; Tocris Bioscience), suspended in 0.5% (w/v) carboxy-
methylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (v/v) 
polysorbate 80, 0.9% (v/v) benzyl alcohol in deionized water once 
per week. Control mice received only vehicle. The animals were 
exposed to chronic normobaric hypoxia (10% O2) in a ventilated 
chamber for 21 days. DACC/CLIC4siRNA or DACC control non-
targeting siRNA were delivered via intravenous injection (2.8 mg/kg 
body weight) twice a week. Single injection of fluorescently labeled 
DACC/siRNA-Cy3 (2.8 mg/kg body weight) in healthy mice was 
used to follow distribution of siRNA in lungs, heart, liver, and kidney 
4 hours and 24 hours post-injection. Localization of the fluorescent 
mimic to the endothelium was confirmed by co-immunostaining for 
VWF (von Willebrand Factor). Preparation and characterization of 
siRNA lipoplexes was performed as described.18
In the second group, Sugen/hypoxia mice (n=8/group) were inject-
ed every other day intraperitoneally either with vehicle (20% DMSO 
and 10% Tween-20) or SecinH3 (100 μL of 5 mmol/L, 2849, Tocris 
Bioscience) dissolved in the vehicle. The normoxic control group re-
ceived vehicle only. Following 21-day hypoxic exposure, the animals 
were removed from the hypoxic chamber individually and anesthetized 
by intraperitoneal injection of Ketamine/Dormitor (75 mg/kg+1 mg/kg).
In the third group, male Sprague-Dawley rats (190–200 g, n=6/
group) were injected subcutaneously with a single dose of monocro-
taline (60 mg/kg body weight). Eight days after monocrotaline in-
jection, 6 rats were injected intraperitoneally every other day with 
vehicle (20% DMSO and 10% Tween-20), while the other group 
(n=6) was injected with SecinH3 (2.5 mg/kg body weight) dissolved 
in vehicle, for a total of 14 days. Control rats (no monocrotaline ) 
were injected with vehicle intraperitoneally every other day. After 
21 days of the study, rats were anesthetized with fentanyl/fluanisone 
(Hypnorm, VetaPharma) using intramuscular injection at 1 mL/kg 
body weight; followed by intraperitoneal injection with 0.8 mL/kg 
body weight of midazolam (Hypnovel, Roche). Changes in CLIC4, 
Arf6, and BMPRII expression were evaluated at 3, 7, 14, and 21 days 
post-monocrotaline injection.
Development of PAH was assessed by measuring right ventric-
ular systolic pressure (RVSP) in mice and mean pulmonary artery 
pressure in rats and right ventricular hypertrophy (RVH) denoted by 
the right ventricle to left ventricle/septum ratio. In mice, pulmonary 
vascular remodeling (muscularization of small intrapulmonary arter-
ies) was determined by counting all muscularized (showing thickened 
α-SMA-positive media) vessels with a diameter smaller than 50 μm 
in each lung section and expressed as a percent of all (muscularized
+nonmuscularized) vessels. In rats, vascular remodeling was deter-
mined as the proportion of peripheral vessels (<100 μm in diameter) 
with double elastic lamina visualized with elastic van Gieson staining 
(>75% of the circumference as fully muscularized, 25% to 75% as 
partly muscularized) to total vessels counted.
Quantitative Reverse Transcriptase Polymerase 
Chain Reaction
For target mRNA knock down analyses, tissues were dissected im-
mediately after killing of the mice and instantly snap-frozen in liquid 
nitrogen. Twenty-five to 100 ng total RNA was used for quantitative 
reverse transcriptase polymerase chain reaction with the amplicon 
sets listed in Online Data Supplement. Data were calculated by using 
the comparative Ct method.
Statistical Analysis
All experiments were performed at least in triplicate. Data are pre-
sented as means±SEM. Normality of data distribution was assessed 
with Shapiro-Wilk test in GraphPad Prism 7.03. Comparisons be-
tween 2 groups were made with Student t test or Mann-Whitney’s 
U test, whereas ≥3 groups were compared by use of ANOVA with 
Tukey’s post hoc test or Kruskal-Wallis with Dunn’s post hoc test, as 
appropriate. Statistical significance was accepted at P<0.05.
Results
CLIC4 Associates With Protein Regulators of Nf-κB 
Signaling and Vesicular Trafficking
To identify potential therapeutic targets in the CLIC4 signal-
ing pathway, we performed a proteomic screen of CLIC4-
interacting proteins, using C-terminal hemagglutinin tag as 
bait. The identified set of proteins included p65NF-kB and 
key regulators of the endocytotic pathway such as Arf6 GAP 
proteins (GIT1 and GIT2), clathrin heavy chain, dynein, ac-
tin crosslinking proteins, and tubulin (Table; Online Table II). 
The association of CLIC4 with clathrin heavy chain and GIT1 
was verified by co-immunoprecipitation followed by Western 
blotting (Online Figure I). Further, direct binding between 
CLIC4 and GIT1 was confirmed using microscale thermo-
phoresis. Microscale thermophoresis permits a robust analysis 
of protein-protein interactions in cell lysates and determina-
tion of their binding affinity (denoted by Kd values), thereby 
quantitating the interaction in a close-to-native context.19 The 
estimated Kd for the interaction between CLIC4 and GIT1 was 
1.8±0.3 μmol/L (Online Figure II), while no binding was ob-
served in BSA control.
To gain a better understanding of CLIC4 function, we per-
formed a label-free GeLCMS proteomic analysis20 of CLIC4-
overexpressing HPAECs. Differentially expressed proteins 
showed pathway association with endocytotic trafficking, ly-
sosomal degradation, NF-κB, and TNF-α signaling (Online 
Table III). Standardized CLIC4 expression levels and changes 
in the expression of selected proteins were confirmed by 
Western blotting (Online Figure III).
Table. CLIC4-Interacting Proteins Involved in the Regulation of Endocytotic 
Trafficking
Protein NP Code
Actin-related protein 2/3 complex NP_005711.1
*ADP-ribosylation factor-like protein 6-interacting 
protein 4
*NP_061164.2
*Arf GTPase-activating protein GIT1 *NP_001078923.1
*Arf GTPase-activating protein GIT2 *NP_001128686.1
Autophagy-related protein 2 homolog B NP_060506.5
*Basement membrane-specific heparin sulphate 
proteoglycan
*NP_005520.4
Chloride intracellular channel protein 1 NP_001279.2
*Clathrin heavy chain 1 *NP_004850.1
Dynein heavy chain 14, axonemal NP_001364.1
Dynein heavy chain 5, axonemal NP_001360.1
Lysosomal-trafficking regulator NP_000072.2
RAD51-associated protein 2 NP_001092688.1
Serine/threonine-protein kinase SMG1 NP_055907.3
Trafficking kinesin-binding protein 1 NP_001073946.1
Microtubule-actin cross-linking factor 1 NP_036222.3
Full list of interacting proteins is provided in Online Table II. *Proteins showed 
a large difference between controls and adCLIC4 (ie, at least 5 peptides in 
adCLIC4 but none in adcontrol). The remaining proteins were detected with 2 to 
4 peptides in AdCLIC4 and none in controls. n=5.
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CLIC4 Reduces BMPRII Expression and Signaling 
and Enhances Inflammatory Responses in HPAECs
Reduced BMPRII signaling and activation of the inflam-
matory transcription factor NF-κB play a central role in the 
pathogenesis of PAH. CLIC4 overexpression markedly en-
hanced hypoxia-induced activation of NF-κB but had little 
additional effect on TNF-α-stimulated cells, possibly because 
the response was already maximal under these conditions. 
CLIC4shRNA and the NF-κB inhibitor, BAY 117085, reduced 
NF-κB activity in all experimental conditions (Figure 1A). 
NF-κB activation was accompanied by increased nuclear lo-
calization of p65NF-κB (Online Figure IV).
CLIC4 markedly reduced protein levels of BMPRII 
(Figure 1B; Online Figure V) and reduced phosphorylation of 
Smad1 and Smad5 in response to BMP9 stimulation (Figure 1C). 
CLIC4 also augmented TGF-β-induced phosphorylation of 
Smad3 (Figure 1D), possibly as a result of contemporary inhi-
bition of BMPRII signaling. Overexpression of BMPRII had no 
effect on CLIC4-induced NF-κB activation, but overexpression 
of serine phosphatase PPM1A, a protein thought to compete 
with CLIC4 for NF-κB binding,6 had an inhibitory effect in all 
experimental conditions (Figure 1E; Online Figure VI)
To investigate whether the effects of CLIC4 on NF-κB 
activity can be related to changes in anion flux, we meas-
ured plasma membrane anion permeability in CLIC4-
overexpressing normoxic and hypoxic HPAECs. CLIC4 
induced a modest (≈2-fold) increase in plasma membrane an-
ion permeability in both normoxic and hypoxic cells (Online 
Figure 1. CLIC4 increases NF-κB activity and reduces BMPRII signaling in HPAECS. A, NF-κB activity in HPAECs overexpressing CLIC4 or CLIC4shRNA 
in normoxia, hypoxia, and in cells treated with TNF-α (10 µg/L, 24 h) or NF-κB inhibitor, BAY 117085 (10 µmol/L, 24 h); luciferase reporter assay. (B) BMPRII 
protein levels, (C) Smad1/5 phosphorylation, and (D) Smad3 phosphorylation in HPAECs infected with Adcontrol or AdCLIC4. In (C), the cells were treated 
with BMP9 (10 µg/L, 1 h) and in (D) with TGF-β (10 µg/L, 1 h). Representative Western blots are shown underneath the graphs. E, The effect of BMPRII and 
PPM1A overexpression on CLIC4-induced activation of NF-κB in cells treated, as indicated. *P<0.05; **P<0.01, ***P<0.001, ****P<0.0001, comparisons with 
Adcontrol; #P<0.05; ##P<0.01; ###P<0.001, comparisons with CLIC4+TNF-α or as indicated. Data are presented as mean±SEM; n=4–8. Student t test 
or 1-way ANOVA with Tukey’s post-test, as appropriate. BMP9 indicates bone morphogenetic protein 9; BMPRII, bone morphogenetic protein receptor II; 
CLIC4, chloride intracellular channel 4; HPAECs, human pulmonary artery endothelial cells; PPM1A, protein phosphatase 1A; NF-κB, nuclear factor kappa B; 
and TNF-α, tumor necrosis factor α.
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Figure VII). In comparison, CLIC4 overexpression elicited a 
differential NF-κB response, such that it induced a much more 
pronounced (≈40-fold) increase in NF-κB activity in hypoxic 
versus normoxic cells (Figure 1A). CLIC4-induced decrease 
in BMPRII expression was unaffected by chloride channel 
blocker indanyloxyacetic acid 94 (Online Figure VIII).
CLIC4 Redirects Endosomal Cargo to Lysosomal 
Degradation
The involvement of CLIC4 in the regulation of endocytotic 
pathway and lysosomal trafficking documented by proteomic 
analysis was verified in a number of functional assays in cul-
tured HPAECs. Proximity ligation assay showed close co-
localization of BMPRII and CLIC4 in LAMP1-positive late 
endosomes/lysosomes, which was increased upon CLIC4 
overexpression (Figure 2A through 2C). CLIC4 increased en-
dosomal/lysosomal acidification and increased the levels of 
LAMP1-positive lysosomes (Figure 2D; Online Figure IX).
Proteomic analysis identified clathrin as one of the 
CLIC4-interacting proteins. Clathrin regulates internalization 
and trafficking of numerous membrane receptors,21 including 
Figure 2. The effect of CLIC4 on intracellular localization of BMPRII, lysosomal function, and clathrin-mediated vesicular trafficking. Confocal images 
and graph in (A) show increased colocalization of BMPRII and CLIC4 in CLIC4-overexpressing cells; proximity ligation assay (PLA). B, Colocalization of 
CLIC4 and BMPRII in LAMP1-positive vesicles, PLA. Boxed area in the left image is magnified in the middle and right images, which show colocalization 
of BMPRII with CLIC4 (white pixels, middle image) or colocalization of CLIC4 and BMPRII (red) with LAMP1 (green) in the right image. Arrowheads indicate 
colocalization points with 1 enlarged colocalization point in the inset in the right image. C, Endosomal/lysosomal acidification; D, clathrin-mediated uptake 
of Alexa488-transferrin. E, Single confocal images of YFP-GGA1  (yellow fluorescent protein–labelled golgi-associated, gamma adaptin ear-containing, 
ARF-binding protein 1) vesicles (left), sum projection images from image stacks (middle), and trajectories of YFP-GGA1 vesicles (right) in cells treated, as 
indicated; F, levels of gyrating clathrin (G-clathrin) in control and CLIC4-overexpressing HPAECs, with or without Sec7 inhibitor H3 (SecinH3; 10 mg/L), as 
indicated. In all images Bar=10 µm. **P<0.01, ***P<0.001, Student t test, or 1-way ANOVA with Tukey’s post-test, as appropriate; n=4–6. Data are presented 
as mean±SEM. BMPRII indicates bone morphogenetic protein receptor II; CLIC4, chloride intracellular channel 4; HPAECs, human pulmonary artery 
endothelial cells; and LAMP1, lysosomal-associated membrane protein 1.
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TfR (transferrin receptor) and BMPRII. In HPAECs, CLIC4 
enhanced clathrin-mediated internalization of fluorescently 
labeled transferrin, without affecting clathrin-independent16 
internalization of MHC-I (Figure 2E; Online Figure IX). To 
further validate the role of endocytotic receptor internalization 
in CLIC4-induced changes in BMPRII expression, CLIC4-
overexpressing cells were treated with endocytosis inhibitor 
Pitstop2,16,22 together with protein synthesis inhibitor, cyclo-
heximide. BMPRII is constitutively internalized in HPAECs, 
and treatment with protein synthesis inhibitor cycloheximide 
for 2 hours results in complete depletion of the intracellular 
pool of BMPRII.23 Pitstop2 restored BMPRII expression in 
CLIC4-overexpressing cells (Online Figure X).
Recent findings show that a submembrane population of fast-
moving clathrin vesicles called gyrating clathrin is responsible 
for directing the cargo of sorting endosomes directly to the cell 
surface and that changes in clathrin light or heavy chains or de-
stabilization of Arf6 GDP-GTP cycle compromise its function.15 
We measured the levels of G-clathrin by analyzing motility of 
YFP-GGA1-labeled intracellular vesicles in the presence of the 
fungal metabolite, brefeldin. G-clathrin structures are brefeldin-
resistant and colocalize (≈97%) with expressed YFP-GGA1, a 
guanine nucleoside exchange factor for Arf6 and therefore can 
be analyzed separately from other endosomal structures and 
Golgi vesicles.24 Time lapse recording of the highly motile YFP-
GGA1-positive vesicles in live cells showed that CLIC4 overex-
pression reduced the pool of gyrating clathrin in HPAECs, while 
treatment of cells with Arf GEF inhibitor, SecinH3, prevented 
this effect (Figure 2E and 2F). SecinH3 inhibits the activity of 
Arf GEFs, cytohesins 1 to 3, by binding to their Sec7 domain, 
without formation of a complex with Arf.25,26
To summarize, CLIC4 augmented internalization of 
BMPRII into the endosomal and lysosomal compartments 
and inhibited G-clathrin, critical for the recycling of the endo-
somal cargo back to the plasma membrane.
CLIC4 Effects Are Mediated by Arf6
We found that CLIC4 interacts with the Arf6 GAPs, GIT1 and 
GIT2, the key regulators of receptor trafficking at the plasma 
membrane.12 While GIT1 and GIT2 co-localize with and specif-
ically activate Arf6,27 they may show some catalytic activity to-
ward Arf1.28 Arf1 and Arf6 differ in their function and subcellular 
localization: Arf1 localizes to and acts within Golgi, whereas 
Arf6 localizes to and acts at the cell periphery.29 We measured 
Arf6 and Arf1 activity and expression in CLIC4-overexpressing 
cells and observed that CLIC4 increased Arf6 activity 3-fold 
without affecting the activity or expression of Arf1 (Figure 3A 
through 3C). No cross-reactivity between anti-Arf1 and anti-
Arf6 antibodies was detected (Online Figure XI). Treatment 
of CLIC4-overexpressing cells with SecinH3 and Arf6 siRNA 
restored BMPRII expression, while Arf1 siRNA had no effect, 
indicating that CLIC4-mediated regulation of BMPRII expres-
sion is Arf6-specific (Figure 3A through 3C). SecinH3 and 
Arf6siRNA prevented CLIC4-induced activation of NF-κB, 
HIF, and tube formation in vitro (Figure 3D and 3E; Online 
Figure XII). Arf1siRNA did not affect CLIC4-induced respons-
es, though it had some inhibitory effect on TNF-α-induced NF-
κB activation and endothelial tube formation (Figure 3E; Online 
Figure XII), likely to result from its key role in the regulation of 
Golgi dynamics. Collectively, these results confirm the role of 
Arf6 as a key mediator of CLIC4-induced responses.
Importantly, ECFCs from idiopathic PAH patients showed 
10-fold increase in Arf6 activity and 5-fold increase in CLIC4 
expression, compared with the cells from healthy volunteers 
(Figure 3F), suggesting a potential role for this pathway in 
human disease.
Lung Endothelium-Targeted Liposomal Delivery 
of CLIC4siRNA Attenuates Development of PH, 
Reduces NF-κB Activity, and Restores Lung 
Expression of BMPRII in Sugen/Hypoxia Mice
To assess the functional role of CLIC4/Arf6 in experimental 
models of PAH, we used DACC siRNA delivery system to 
target CLIC4siRNA to the lung endothelium.18 The analysis 
of the tissue distribution of siRNA-Cy3-labeled DACC for-
mulation confirmed that DACC directs the siRNA predomi-
nantly to the lung endothelium (Figure 4D; Online Figure 
XIII), consistent with previously published data.18 Treatment 
with DACC/CLIC4siRNA formulation significantly reduced 
CLIC4 mRNA and protein levels in the lungs of these animals 
(Online Figure XIV).
Sugen/hypoxia induced a significant increase in RVSP, 
RVH, and intrapulmonary small vessel muscularization 
marked by prominent α-SMA staining seen in normally non-
muscularized, precapillary arterioles (Figure 4A through 4C 
and 4E; Online Figure XV). These changes were accompanied 
by a marked activation of Arf6 and Arf1, increase in CLIC4 
expression, and reduction in protein expression of BMPRII 
(Figure 4F through 4I). DACC/CLIC4 siRNA markedly re-
duced RVSP (P<0.05), RVH (P<0.001), and vascular mus-
cularization (P<0.001), while control, nontargeting siRNA 
had no significant effect (Figure 4A through 4C and 4E). 
Consistent with the effects observed in cultured cells, the 
in vivo application of CLIC4siRNA markedly reduced Arf6 
activity, increased BMPRII expression, and reduced NF-κB 
activation in the lung but had no significant impact on Arf1 
activity (Figure 4F through 4I; Online Figure XIV). Protein 
levels of Arf6 and BMPRII mRNA levels were not affected by 
the treatment (Online Figure XIV and data not shown).
SecinH3 Prevents Development of PH in Sugen/
Hypoxia in Mice and Attenuates Symptoms of 
Disease in Monocrotaline Rats
Intraperitoneal delivery of SecinH3 reduced RVSP, RVH, and 
reduced pulmonary muscularization in Sugen/hypoxia mice 
(Figure 5A through 5D; Online Figure XVI). This effect was 
associated with increased BMPRII expression and reduced ac-
tivity of Arf6 and NF-κB in the lung (Figure 5E through 5H; 
Online Figure XVII). Interestingly, Arf1 was also activated in 
PH lungs, and its activity was reduced by SecinH3 (Figure 5F).
We next assessed the efficacy of SecinH3 treatment in the 
monocrotaline rat model of PAH, a nongenetic model of disease 
in which activation of NF-κB and reduction of BMPRII expres-
sion play a central role.30,31 The treatment regime started 8 days 
after a single injection of monocrotaline , when the pathologi-
cal processes leading to vascular remodeling are already estab-
lished.32 Increase in CLIC4 expression and Arf6 activation were 
noted from day 3, while significant rise in mean pulmonary 
artery pressure was noted later—14 days post-monocrotaline 
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injection (Online Figure XVIII). SecinH3 significantly im-
proved RVSP, RVH, and reduced arterial muscularization 
(Figure 6A through 6D; Online Figure XIX). These changes 
were accompanied by a marked reduction in Arf6, Arf1, and 
NF-kB activity and restoration of BMPRII expression without 
changes in CLIC4 expression in the lung (Figure 6E through 
6H; Online Figure XX). SecinH3 did not cause any noticeable 
side effects or changes in the heart, liver, lung, kidney, spleen, 
or pancreas of treated animals (Online Figure XXI).
Discussion
This study shows for the first time that CLIC4 and Arf6 act to-
gether at the intersection of BMPRII and NF-κB signaling in 
PAH. We report a novel pathway through which BMPRII ex-
pression can be regulated, involving CLIC4/Arf6-dependent 
changes in receptor trafficking (Figure 7). We also demon-
strate increased activity of CLIC4/Arf6 in ECFCs from idio-
pathic PAH patients and in lung tissues from Sugen/hypoxia 
mice and monocrotaline rats and show the effectiveness of 
Figure 3. Arf6 mediates the effects of CLIC4. A, Arf6 activity; B, BMPRII expression in control HPAECs (Adcontrol), HPAECs overexpressing CLIC4 
(AdCLIC4), with or without Sec7 inhibitor H3 (SecinH3; 10 mg/L, 24 h), as indicated. Representative Western blots are shown on the right. Graph in (C) and 
corresponding representative Western blots show the effect of control siRNA (ctrl siRNA), Arf6 siRNA, and Arf1 siRNA on BMPRII levels in Adcontrol- and 
AdCLIC4-overexpressing cells. D, The effect of SecinH3 on TNF-α-induced activation of NF-κB in control and CLIC4-overexpressing HPAECs; E, The effect 
of Arf6 siRNA and Arf1 siRNA on TNF-α-induced activation of NF-κB in cells treated, as indicated. F, Arf6 activity and CLIC4 expression in ECFCs from 
IPAH patients, n=6. *P<0.05, **P<0.01, ***P<0.001, comparisons with Adcontrol; #P<0.05; ##P<0.01; ###P<0.001, comparisons with AdCLIC4+TNF-α or 
as indicated. Data are presented as mean±SEM; n=4–6. Student t test or 1-way ANOVA with Tukey post hoc test, except for (F), where data were analyzed 
with Mann-Whitney U test. Arf6 indicates ADP ribosylation factor 6; BMPRII, bone morphogenetic protein receptor II; CLIC4, chloride intracellular channel 4; 
HPAECs, human pulmonary artery endothelial cells; NF-κB, nuclear factor kappa B; and TNF-α, tumor necrosis factor α.
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CLIC4/Arf6 targeting in the treatment of the disease in 2 dif-
ferent preclinical models of PAH.
Dysfunctional endocytosis and recycling of cell-surface 
proteins is gradually being recognized as a hallmark of prolif-
erative and inflammatory disorders, including atherosclerosis, 
PH, and malignant cancers.23,33 Once endocytosed into early 
endosomes, signal transduction receptors are either sorted into 
a recycling pathway that returns the molecules to the cell sur-
face for another round of signaling or are sorted into a degra-
dative pathway to be degraded in the lysosome.
Arf6, like other Arf proteins (Arf1-6), is regulated through 
the activation by GEFs and inhibition by GAPs. Physical 
interaction between CLIC4 and GIT proteins is likely to 
interfere with GIT-mediated GTP hydrolysis, resulting in the 
observed stabilization of an active, GTP-bound Arf6. Kd value 
for GIT1-CLIC4 interaction is in the low micromolar range, 
comparable with typical Kd values for ArfGAP-Arf interac-
tion.34 As crystal structure of GIT proteins or the mechanism 
of GTP hydrolysis have not been fully characterized, the pre-
cise nature of CLIC4-GIT-Arf6 interaction will require further 
studies.
Our results indicate that CLIC4-induced inhibition of 
BMPRII signaling can be attributed to Arf6. Similarly, Arf6 
but not Arf1 has been shown to terminate signaling of epider-
mal growth factor and luteinizing hormone receptors by short-
ening their lifetime at the cell membrane.35,36 Arf6-mediated 
Figure 4. Effects of CLIC4siRNA on development of pulmonary hypertension, Arf activation, BMPRII expression, and NF-κB activity in Sugen/
hypoxia mice. (A) RVSP; (B) RV/LV+S; and (C) percentage of muscularized vessels in lungs of control mice and Sugen/hypoxia mice treated with 
nontargeting siRNA (control siRNA) or CLIC4 siRNA/DACC lipoplex, as indicated. D, Confocal images showing endothelial localization of nontargeting 
fluorescent siRNA delivered by DACC delivery vehicle (siRNACy3/DACC); Bar=10 μm. E, αSMA staining in mouse lung sections. Arrowheads point to 
small intrapulmonary vessels. Bar=25 μm. F–H, Graphs and corresponding representative Western blots show Arf6 and Arf1 activity, CLIC4, and BMPRII 
expression in lungs of the untreated and CLIC4siRNA-treated mice, as indicated. I, NF-κB activity in mice treated, as indicated. *P<0.05, **P<0.01, 
***P<0.001, comparisons with controls; #P<0.05, ###P<0.001 comparisons with control siRNA Sugen/hypoxia group or as indicated. Data are presented as 
mean±SEM; n=7–8. One-way ANOVA with Tukey post hoc test. Arf6 indicates ADP ribosylation factor 6; BMPRII, bone morphogenetic protein receptor II; 
CLIC4, chloride intracellular channel 4; NF-κB, nuclear factor kappa B; LV, left ventricle; RV, right ventricular; RVSP, right ventricular systolic pressure; and 
VWF, von Willebrand Factor.
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internalization of membrane receptors and their subsequent 
targeting for lysosomal degradation can be prompted by pro-
teolytic cleavage.37 Of relevance, Kaposi sarcoma-associated 
herpesvirus, which has been associated with the development 
of PAH, induces ubiquitination of BMPRII that leads to ly-
sosomal degradation of the receptor.4 The precise contribu-
tion of CLIC4, which binds ubiquitin conjugation factor E4 
A and alters expression of ubiquitin thioesterase ZRANB1, 
E3 ubiquitin-protein ligases RNF6 and TRAF7, to proteo-
lytic degradation of membrane receptors will require further 
investigation.
Clathrin coat formation is governed by a complex web 
of reversible protein-protein interactions that engage under 
tight temporal and spatial regulation. Dysregulation of almost 
any component of the endocytic machinery often results in 
its complete collapse because of the unregulated sequestra-
tion of one or more interaction partners. Whether reduction in 
gyrating clathrin is a cause or a consequence of this dysregula-
tion remains to be established. The association of CLIC4 with 
clathrin heavy chain or destabilization of Arf6 GTP-GDP ex-
change through interaction with GIT1 and GIT2 may reduce 
the levels of gyrating clathrin.15
Although CLIC proteins lack a recognizable signal se-
quence, they can induce chloride currents in artificial mem-
brane systems under nonreducing conditions. This has led 
to the hypothesis that soluble CLICs can adopt an integral 
membrane conformation to form chloride channels under cer-
tain conditions. However, the channel hypothesis remains a 
Figure 5. Effects of Sec7 inhibitor H3 (SecinH3) on development of pulmonary hypertension, Arf activation, BMPRII expression, and NF-κB activity 
in Sugen/hypoxia mice. A, RVSP; (B) RV/LV+S, and (C) percentage of muscularized vessels in lungs of control mice and Sugen/hypoxia mice treated with 
SecinH3, as indicated. D, αSMA staining in mouse lung sections. Arrowheads point to small intrapulmonary vessels. Bar=25 µm. (E) Arf6 activity, (F) Arf1 
activity, and (G) BMPRII expression in the lungs of untreated and SecinH3-treated mice, as indicated. Representative Western blots are shown below the 
graphs. H, NF-κB activity in mice. *P<0.05, **P<0.01, ***P<0.001, comparisons with controls; #P<0.05, ##P<0.01, ###P<0.001 comparisons, as indicated. 
Data are presented as mean±SEM; n=8. One-way ANOVA with Tukey post hoc test. Arf6 indicates ADP ribosylation factor 6; BMPRII, bone morphogenetic 
protein receptor II; NF-κB, nuclear factor kappa B; LV,left ventricle; RV, right ventricle; and RVSP, right ventricular systolic pressure.
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matter of debate, and it seems likely that CLIC proteins have 
other cellular functions that are distinct from their proposed 
roles as chloride channels.9 While CLIC4 overexpression in-
creased plasma membrane anion permeability in HPAECs, 
it is not clear whether this change was caused by CLIC4 or 
by subsequent activation of other transporters. The observed 
changes in anion conductance did not correspond to the 
changes in NF-κB activity or BMPRII expression, suggest-
ing that anion conductance is not a major contributing fac-
tor. In addition, chloride channel blocker, indanyloxyacetic 
acid 94, did not affect CLIC4-induced changes in BMPRII 
expression. However, we cannot exclude the possibility that 
Figure 6. Effects of Sec7 inhibitor H3 (SecinH3) on development of pulmonary hypertension, Arf activation, BMPRII, and CLIC4 expression in lungs 
of MCT rats. (A) mPAP; (B) RV/LV+S; and (C) percentage of remodeled vessels in lungs of control and MCT rats treated with SecinH3, as indicated. D, Elastic 
van Gieson (EVG) staining showing fully muscularized peripheral arteries with double elastic laminae in MCT rat lung but single elastic laminae in control and 
SecinH3-treated rat lung (arrowheads). Bar=25 µm. E, Arf6 activity, (F) Arf1 activity, (G) BMPRII expression, and (H) NF-κB activity. Representative Western 
blots are shown below the graphs. *P<0.05, **P<0.01, ***P<0.001, comparisons with controls; #P<0.05, ##P<0.01, ###P<0.001 comparisons, as indicated. 
Data are presented as mean±SEM; n=6. One-way ANOVA with Tukey post hoc test. Arf6 indicates ADP ribosylation factor 6; BMPRII, bone morphogenetic 
protein receptor II; CLIC4, chloride intracellular channel 4; MCT, monocrotaline; and NF-κB, nuclear factor kappa B.
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CLIC4 ion channel activity may affect immune responses in 
vivo. CLIC1−/− macrophages show reduced phagocytosis, pos-
sibly associated with defective acidification of phagosomes.38 
Consistent with the activation of lysosomal pathway, we ob-
served increased numbers and acidification of lysosomes in 
CLIC4-overexpressing cells. Of interest, in endothelial cells, 
CLIC4 supports intravesicular acidification and vacuolar fu-
sion through an unknown mechanism.7
CLIC4 increases serine phosphorylation of p65NF-κB5 re-
quired for its nuclear translocation, and we observed that serine 
phosphatase PPM1A had an inhibitory effect, reinforcing the 
view of potential involvement of this protein in CLIC4 signal-
ing.6 Interestingly, we also observed that the pro-inflammatory 
effects of CLIC4 required the activity of Arf6. The exact mech-
anism is not known but may involve Arf6-mediated internali-
zation of cytokine receptors.39 While silencing of BMPRII did 
not affect CLIC4-induced NF-κB activation in vitro, it is likely 
that some regulatory feedback mechanisms operate in vivo. 
BMPRII deletion reduces expression of superoxide dismutase 
in the vasculature,40 leading to increased ROS generation and 
DNA damage, known to stimulate CLIC4 expression.
The contribution of CLIC4/Arf6 pathway to vascular dys-
function is likely to extend beyond the regulation of BMPRII 
and NF-κB signaling. Both CLIC4 and Arf6 play regulatory 
roles in pathways enhancing cell proliferation, migration, in-
crease endothelial permeability, angiogenesis, and are pre-
dictors of poor prognosis in cancer.5,41–43 Accordingly, Arf6 
siRNA and SecinH3 inhibited CLIC4-induced HIF activation 
and angiogenic responses in cultured HPAECs. CLIC4 and 
Arf6 are activated by angiotensin II44,45 and mediate the effects 
of TGF-β.6,46 We noted a marked upregulation of CLIC4 
and Arf6 signaling in ECFCs from idiopathic PAH patients 
(5- and 10-fold increase, respectively), suggesting potential 
importance of this pathway in the human condition. ECFCs 
represent an accessible surrogate cell type to study endothelial 
dysfunction in PAH and display several characteristics of the 
disease, including reduced BMPRII expression, disorganized 
angiogenesis, increased permeability, increased HIF and NF-
κB activation, which also represent responses augmented by 
CLIC4/Arf6 signaling.
Importantly, we show that CLIC4 expression in the lung 
vasculature can be targeted using the DACC siRNA delivery 
system. DACC/CLIC4 siRNA treatment reduced Arf6 but 
not Arf1 activity, restored BMPRII expression, and attenu-
ated the development of PH in Sugen/hypoxia mice. These 
experiments confirm a critical role of CLIC4/Arf6 pathway 
in disease pathogenesis and demonstrate therapeutic poten-
tial of gene targeting by RNA interference. Further, we show 
that pharmacological targeting of CLIC4/Arf6 signaling with 
SecinH325 prevents CLIC4-induced effects in vitro (inset in 
Figure 7) and attenuates development of PH in Sugen/hy-
poxia mice and monocrotaline rats. SecinH3 was developed 
as a specific inhibitor of small sec7 containing GEFs such 
as Arf-GEFs, which prevents Arf6 activation by inhibiting 
GDP for GTP exchange with dissociation constants (Kd val-
ues) between 200 and 250 nmol/L.25 Preclinical studies show 
that SecinH3 and other inhibitors of cytohesins are effective 
in treatment of inflammatory and hyperproliferative diseases. 
While we did not observe any detrimental effects of SecinH3 
treatment in our study, cytohesin inhibitors were shown to 
Figure 7. Proposed CLIC4/Arf6 signaling pathway. Arf6 indicates ADP ribosylation factor 6; BMPR, bone morphogenetic protein receptor; CLIC4, 
chloride intracellular channel 4; GAPs, GTPase-activating proteins; GEFs, guanine exchange factors; PAH, pulmonary arterial hypertension; PPM1A, protein 
phosphatase 1A; NF-κB, nuclear factor kappa B; and TGF-β, transforming growth factor.
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increase insulin resistance in mice.25 Antiproliferative ef-
fects of SecinH3 correlate with a profound inhibition of Akt 
activation and survivin expression in lung cancer.47 SecinH3 
has also been shown to reduce lung injury in septic rats and 
increase vascular stability in mouse models of arthritis.48,49 
In addition to the inhibition of Arf6, which localizes to the 
plasma membrane, SecinH3 may also inhibit the activity of 
Golgi-localized Arfs (Arf 1,3,4,5). Activation of Arf1 in PH 
lungs is likely to reflect the importance of Golgi-dependent 
protein trafficking in vascular remodeling. The role of Arf-
regulated Golgi dynamics and the effect of cytohesin inhibi-
tors on trafficking of other membrane receptors involved in 
PH pathogenesis will require further studies.
In summary, we identify a novel pathway involving acti-
vation of the endocytotic trafficking regulator, Arf6. Inhibition 
of CLIC4/Arf6 pathway represents a novel strategy in treat-
ment of PAH.
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